ROCKAWAY, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.
Wednesday, May 3, 2023, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13738144
Webcast: electroCore Earnings Webcast
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:
Rich Cockrell
CG Capital
404-736-3838
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.02 |
| Daily Change: | 0.04 0.67 |
| Daily Volume: | 57,195 |
| Market Cap: | US$39.430M |
March 12, 2025 February 27, 2025 February 06, 2025 January 07, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
